Hypertrophic Cardiomyopathy Webinars
Learn more about HCM so you are better able to discuss its impact with your patients through this free webinar series. Be sure to check here for live webinar registration opportunities as dates are confirmed.
Improving Clinical Recognition of HCM: The Pursuit of Accurate Diagnosis
October 19, 2021 at 1:00 PM Central
Presenters: Matthew Martinez, MD, FACC; Anjali Tiku Owens, MD; Sharon Cresci, MD, FAHA, FACC, FASE
Moderator: James E. Udelson, MD, FAHA
HCM is a chronic disease that can progress to cardiac dysfunction and the clinical syndrome of heart failure. It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed?
Bristol Myers Squibb is a national sponsor of the American Heart Association’s hypertrophic cardiomyopathy initiative.
Enduring Webinars
Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
Presenters: Martin S. Maron, MD; Marye Gleva, MD
Moderator: James E. Udelson, MD, FAHA
Some people with HCM are at increased risk for developing atrial fibrillation, heart failure, suffering from stroke and even sudden cardiac death (SCD). Patients who suffer from arrhythmias associated with HCM may require implantable cardioverter-defibrillator devices to reduce their risk of SCD. Join Drs. Maron, Gleva, and Udelson as they discuss risk stratification strategies, device selection, and the role of shared decision-making in the prevention of SCD.
Imaging for the Diagnosis and Management of Hypertrophic Cardiomyopathy
Presenters: Theodore Abraham, MD; Ethan Rowin, MD
Moderator: James E. Udelson, MD, FAHA
Hypertrophic cardiomyopathy is the most common form of genetic heart disease and can affect people of any age, yet it often goes undiagnosed. Diagnosis is typically done by echocardiogram to assess the thickness of the heart muscle and observe blood flow in and out of the heart.
Viewers will learn about the role of imaging in the diagnosis and treatment of patients with HCM.
Clinical Implications of Genetic Testing in Hypertrophic Cardiomyopathy
Presenters: Dr. Anjali Owens, Dr. Sharon Cresci
Moderator: Dr. James Udelson
Summary: It is estimated that 1 in every 500 adults living in the U.S. have HCM, but a large percentage of patients are undiagnosed. Which of your patients is undiagnosed? Hypertrophic Cardiomyopathy (HCM) is the most common form of genetic heart disease and can affect people of any age. HCM can be a debilitating and life-changing disease. People with HCM are often forced to make lifestyle changes, such as limiting their activity, to accommodate their disease. Sometimes this accommodation might not even be noticed by the patient themselves meaning careful questioning of symptoms and changes in activity are critical.
Learn more about HCM in this free webinar so you are better able to discuss its impact with your patients.
Hypertrophic Cardiomyopathy: An Introduction and Overview
Presenters: Dr. Sharon Cresci, Dr. Robert Fraser
Moderator: Dr. James Udelson
Summary: Hypertrophic cardiomyopathy or HCM is a primary myocardial disorder defined by left ventricular (LV) hypertrophy that cannot be explained by another cardiac or systemic disease. Some people with HCM experience symptoms such as fatigue, fainting, shortness of breath, chest pain or palpitations. Others with HCM do not experience any symptoms. Listen to experts as they explore the HCM symptoms, epidemiology, pathophysiology and the burden of the disease on patients and families.
Learn more about HCM in this free webinar so you are better able to discuss its impact with your patients.
American Heart Association's Hypertrophic Cardiomyopathy Initiative is sponsored by Bristol Myers Squibb.